MUNDIPHARMA
Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com.sg .
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter , LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005483/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT and E.ON Extend Partnership to Drive AI-Powered Energy Management Innovation11.11.2025 02:00:00 CET | Press release
Global technology and IT services provider FPT and E.ON Optimum, the digital solutions arm of E.ON UK, under E.ON Group, announced a new agreement to extend their collaboration in digital energy management. The signing marks the next phase of a partnership established in 2022, reaffirming both corporations’ shared vision of harnessing technology to accelerate innovation and sustainability in the energy sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110039775/en/ FPT and E.ON Optimum leaders at the signing ceremony to extend their partnership in AI-powered energy management. Under this agreement, FPT will continue to support the development and operation of E.ON Optimum’s solution platform, a cloud-based energy management system that gives business energy users timely, flexible data analysis, allowing for better and faster decisions on net-zero energy usage. The next phase focuses on maintaining and enhancing web a
Ant International Open Sources Time-Series Transformer AI Model to Enable More Businesses to Benefit from AI-Powered Forecasting11.11.2025 01:30:00 CET | Press release
Ant International currently deploys the Falcon TST AI Model to forecast cashflow and FX exposure with more than 90% accuracy Ant International, a leading global digital payment, digitisation, and financial technology provider, has released its proprietary Falcon TST (Time-Series Transformer) AI model, the industry-first Mixture of Experts architecture-based big data model with multiple patch tokenizers, supported by up to 2.5 billion parameters. The model has also achieved state-of-the-art zero-shot results on well-acknowledged long-term forecasting benchmarks, such as absolute mean error rates. Deployed internally at Ant International to manage cashflow and FX exposure on an hourly, daily and weekly basis, Falcon TST has achieved accuracy rates of over 90%, and cut the company’s FX costs by up to 60%. Ant International also collaborated with various industry partners to deploy the model in different use cases, such as in helping businesses mitigate FX cost and volatility, as well as t
The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More11.11.2025 00:08:00 CET | Press release
The Empire State Building (ESB) today announced its Holiday Celebration plans include: holiday décor, classic movie screenings, local pop-ups, festive tower lightings, and a holiday takeover with the Radio City Rockettes to celebrate the most wonderful time of the year at New York City’s number one attraction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110124149/en/ The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More “There is no better place to celebrate the holidays in New York City than at the Empire State Building Observatory,” said Dan Rogoski, General Manager at the Empire State Building Observatory. “This year, New Yorkers and visitors will enjoy the best of the holiday season in our iconic venue as we celebrate 100 years of the Radio City Rockettes.” Deck the Halls From the grou
Megaport to Acquire Latitude.sh, Creating an Industry-leading Compute and Network-as-a-Service Platform to Power High-performance Applications and AI Workloads Globally10.11.2025 23:17:00 CET | Press release
Megaport Limited (ASX: MP1), the world’s leading Network-as-a-Service (NaaS) provider, today announced it has entered into an agreement to acquire Latitude.sh, a leading global Compute-as-a-Service company delivering high-performance CPU and GPU infrastructure on demand. Following completion of the acquisition, the combined capabilities will create a global platform that unites Megaport’s private, high-speed connectivity fabric with Latitude.sh’s compute infrastructure, enabling enterprises to rapidly deploy and connect critical workloads across more than 1,000 data centres in 26 countries. “Megaport has long been trusted by the world’s largest enterprises to move workloads seamlessly between data centers and the cloud,” said Michael Reid, CEO of Megaport. “By bringing Latitude.sh into the fold, we’re extending that promise beyond the network, and into high-performance, optimized compute, complementing cloud providers. Together, we will not only serve the massive traditional compute ma
Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization10.11.2025 22:49:00 CET | Press release
Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future. This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets. A Strategic Step Toward Circular Bioeconomy Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom